Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis Meglumine in Chinese Participants with ATTR-PN
NCT04828993Phase 4Completed
- Sponsor
- Pfizer
- Start
- Apr 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tafamidis in transthyretin amyloid polyneuropathy (ATTR-PN), sponsored by Pfizer. Started Apr 2021; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid polyneuropathy (ATTR-PN)
Beyond the preview
Go deeper on NCT04828993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828993.